The vaccine maker’s board intends to recommend a pending offer from investment firms Nordic Capital and Permira, which would ...

Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon ...

COPENHAGEN, Denmark, July 31, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consi ...

A consortium led by Nordic Capital and Permira has made an offer of around $3 billion to buy all the shares of Bavarian Nordic , the vaccine maker said on Monday.

Bavarian Nordic acquisition valued at $3 billion: Nordic Capital and Permira’s all-cash offer represents up to a 37.4% premium over the company’s six-month volume-weighted average share price. Deal ...

After what Bavarian Nordic described as “intense negotiations,” the Danish vaccine maker has agreed to be acquired by a private equity consortium in a 19 billion krone ($3 billion) deal ...

Bavarian Nordic, maker of the chikungunya vaccine Vimkunya, is in talks with private equity firms Nordic Capital and Permira about a potential takeover.

The directors of the vaccine maker said the offer from Permira and Nordic Capital was an attractive proposal and recommended ...

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose ...

A consortium led by Nordic Capital and Permira has made an around $3 billion offer to buy all shares in Bavarian Nordic, the ...

Each private equity firm had a corporate adviser, while separate firms provided financing, competition and local counsel.

COPENHAGEN, Denmark, July 22, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like ...